US Stock MarketDetailed Quotes
ORGS Orgenesis
- 0.619
- -0.016-2.49%
Close Jul 25 16:00 ET
- 0.646
- +0.027+4.41%
Pre 08:06 ET
21.31MMarket Cap-465P/E (TTM)
0.680High0.619Low15.24KVolume0.670Open0.635Pre Close9.99KTurnover0.06%Turnover RatioLossP/E (Static)34.43MShares1.17052wk High-0.77P/B16.87MFloat Cap0.25052wk Low--Dividend TTM27.25MShs Float16.800Historical High--Div YieldTTM9.59%Amplitude0.250Historical Low0.655Avg Price1Lot Size
Orgenesis Stock Forum
Sign in to post a comment
$Orgenesis(ORGS.US$ Orgenesis-Enteredinto Asset Purchase and Strategic Collaboration Agreement Which to Provide Octomera With Over $8 Mln of Initial Collaboration Payments
3
1
$Orgenesis(ORGS.US$
NEWS
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform wit...
NEWS
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform wit...
2
2
$Orgenesis(ORGS.US$ Press Release: Orgenesis Consortium Awarded EUR2.0M EUR Grant From Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
Dow Jones· just
Dow Jones· just
$Orgenesis(ORGS.US$ the next 100x underway? I'm looking to see how cell & gene therapy decentralisation will change the pharmaceutical scenes
Investors expect Orgenesis' limited growth rates to persist due to its declining revenue growth and lower P/S ratio compared to industry peers. Without revenue improvement, share price recovery seems unlikely.
$Orgenesis(ORGS.US$Benzinga· 3 mins ago
Orgenesis has entered into a definitive agreement with MM OS Holdings, an affiliate of Metalmark Capital Partners, to acquire its approximate 25% stake in Octomera.
Octomera is Orgenesis's cell processing services subsidiary, and the transaction allows the company to have 100% ownership of this business unit.
In exchange, Metalmark will receive a royalty of 5% of the net revenue of Octomera's cell processing services for the three calendar years 2025-...
Orgenesis has entered into a definitive agreement with MM OS Holdings, an affiliate of Metalmark Capital Partners, to acquire its approximate 25% stake in Octomera.
Octomera is Orgenesis's cell processing services subsidiary, and the transaction allows the company to have 100% ownership of this business unit.
In exchange, Metalmark will receive a royalty of 5% of the net revenue of Octomera's cell processing services for the three calendar years 2025-...
$Orgenesis(ORGS.US$ Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE![]()
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Trytosaveabit OP : Orgenesis Inc - Looking Forward, Our First Major Step in Transformation Was Recent Transaction to Regain 100% Ownership of Octomera